Detalhe da pesquisa
1.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
Blood
; 2024 Feb 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38437498
2.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37441846
3.
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Blood
; 141(2): 156-167, 2023 01 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35714312
4.
Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer
; 2024 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38340331
5.
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Br J Haematol
; 2024 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38603594
6.
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Br J Haematol
; 2024 May 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38724457
7.
Acute myeloid leukaemia.
Lancet
; 401(10393): 2073-2086, 2023 06 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37068505
8.
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Blood
; 139(6): 907-921, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34601571
9.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Blood
; 140(12): 1345-1377, 2022 09 22.
Artigo
Inglês
| MEDLINE | ID: mdl-35797463
10.
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Blood
; 140(16): 1753-1763, 2022 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-35512188
11.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Blood
; 140(21): 2228-2247, 2022 11 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36130297
12.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Blood
; 140(11): 1200-1228, 2022 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35767897
13.
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
Haematologica
; 2024 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38618679
14.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38695144
15.
Hematologic malignancies in Li-Fraumeni syndrome: A case report.
Am J Med Genet A
; : e63573, 2024 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38410872
16.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38361282
17.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38343151
18.
Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Cancer
; 129(4): 531-540, 2023 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36477735
19.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36458426
20.
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Cancer
; 129(7): 1017-1029, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36715486